Streetbeat News

EFTR

eFFECTOR Therapeutics Inc

http://effector.com/

CEO

Steve Worland

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

effector therapeutics is a biotechnology company located in 11180 roselle street, san diego, ca, united states.

Open

0.00

Mkt cap

941

Volume

202K

High

0.00

P/E Ratio

N/A

52-wk high

17.90

Low

0.00

Div yield

N/A

52-wk low

0.00

eFFECTOR Therapeutics has been declared in default on a $75M loan from Oxford Finance. The default notice cites material adverse changes and insolvency, making all obligations immediately due and payable with interest accruing at the default rate.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 10:05 am

U.S. stocks showed mixed performance with the Dow Jones gaining over 300 points, while the NASDAQ fell. Energy shares led the gains, while information technology shares lagged. Alimera Sciences saw a significant spike after announcing an acquisition agreement with ANI Pharmaceuticals. Agrify Corporation and MicroAlgo Inc. also saw substantial gains. Conversely, eFFECTOR Therapeutics, American Rebel Holdings, and Allarity Therapeutics experienced notable declines.

Portfolio Pulse from Avi Kapoor

June 24, 2024 | 5:06 pm

eFFECTOR Therapeutics (EFTR) shares plummeted over 70% after the company announced it will terminate employees, wind down operations, and request delisting from Nasdaq. Craig R. Jalbert has been appointed to oversee the process.

Portfolio Pulse from Henry Khederian

June 24, 2024 | 3:26 pm

EFFECTOR Therapeutics shares are trading lower after the company announced it will terminate its employees and wind down operations. The company also plans to voluntarily request a delisting of its securities on the Nasdaq.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:41 am

eFFECTOR Therapeutics has announced plans to wind down its operations and seek potential strategic alternatives. The company also expects to delist from Nasdaq.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:01 am

12 health care stocks showed significant movements in Tuesday's pre-market session. Sharps Technology, Insmed, and Calliditas Therapeutics were among the top gainers, while Innovative Eyewear and OneMedNet were notable losers.

Portfolio Pulse from Benzinga Insights

May 28, 2024 | 12:07 pm

eFFECTOR Therapeutics and Dana-Farber Cancer Institute are collaborating on a Phase 2 clinical trial to evaluate Zotatifin as a combination treatment for ER+ endometrial cancer and low-grade serous ovarian cancer.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 12:39 pm

eFFECTOR Therapeutics reported Q1 2024 GAAP EPS of $(2.16), slightly beating the $(2.17) estimate. The company also announced a cash runway into Q1 of 2025.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:51 pm

In Thursday's after-market session, several healthcare stocks showed significant movement due to their Q1 earnings reports. Sensus Healthcare, TELA Bio, CareDx, Natera, Sharecare, and ADMA Biologics were among the gainers, with Sensus Healthcare leading with a 33.3% increase. On the downside, Macrogenics experienced the largest drop, falling 55.6%, followed by Progyny, Aesthetic Medical Intl, Clearside Biomedical, eFFECTOR Therapeutics, and Monopar Therapeutics.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 8:31 pm

In Friday's intraday session, several healthcare stocks experienced significant movements. Candel Therapeutics, Galectin Therapeutics, and Ocugen were among the top gainers, with notable increases in their stock prices. Conversely, Acorda Therapeutics, Aesthetic Medical Intl, and Ontrak were among the top losers, experiencing significant declines. The movements were attributed to various factors, including quarterly earnings releases for some companies.

Portfolio Pulse from Benzinga Insights

April 05, 2024 | 4:39 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.